Beneficial effects of SR33805 in failing myocardium

Cardiovasc Res. 2011 Aug 1;91(3):412-9. doi: 10.1093/cvr/cvr096. Epub 2011 Apr 4.


Aims: SR33805, a potent Ca(2+) channel blocker, increases cardiac myofilament Ca(2+) sensitivity in healthy rat cardiomyocytes. Therefore, the aim of the present study was to evaluate the effects of SR33805 on contractile properties in ischaemic failing hearts after myocardial infarction (MI) in vivo and in vitro at the cellular level.

Methods and results: The effect of SR33805 (10 µM) was tested on the excitation-contraction coupling of cardiomyocytes isolated from rat with end-stage heart failure. Cell shortening and Ca(2+) transients were measured in intact cardiomyocytes, while contractile properties were determined in Triton X-100 permeabilized myocytes. Acute treatment with SR33805 restored the MI-altered cell shortening without affecting the Ca(2+) transient amplitude, suggesting an increase of myofilament Ca(2+) sensitivity in MI myocytes. Indeed, a SR33805-induced sensitization of myofilament activation was found to be associated with a slight increase in myosin light chain-2 phosphorylation and a more significant decrease on troponin I (TnI) phosphorylation. Decreased TnI phosphorylation was related to inhibition of protein kinase A activity by SR33805. Finally, administration of a single intra-peritoneal bolus of SR33805 (20 mg/kg) improved end-systolic strain and fractional shortening of MI hearts.

Conclusion: The present study indicates that treatment with SR33805 improved contractility of ischaemic failing hearts after MI in the rat by selectively modulating the phosphorylation status of sarcomeric regulatory proteins, which then sensitized the myofilaments to Ca(2+). Our results gave a proof of concept that manipulation of the Ca(2+) sensitivity of sarcomeric regulatory proteins can be used to improve contractility of a failing heart.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Calcium Channel Blockers / pharmacology
  • Calcium Signaling / drug effects
  • Cardiac Myosins / metabolism
  • Cardiotonic Agents / administration & dosage
  • Cardiotonic Agents / pharmacology*
  • Cyclic AMP-Dependent Protein Kinases / antagonists & inhibitors
  • Cyclic AMP-Dependent Protein Kinases / metabolism
  • Disease Models, Animal
  • Excitation Contraction Coupling / drug effects
  • Heart Failure / diagnostic imaging
  • Heart Failure / drug therapy*
  • Heart Failure / metabolism
  • Heart Failure / physiopathology
  • Indoles / administration & dosage
  • Indoles / pharmacology*
  • Injections, Intraperitoneal
  • Male
  • Myocardial Contraction / drug effects*
  • Myocytes, Cardiac / drug effects*
  • Myocytes, Cardiac / metabolism
  • Myofibrils / drug effects
  • Myofibrils / metabolism
  • Myosin Light Chains / metabolism
  • Phosphorylation
  • Protein Kinase Inhibitors / pharmacology
  • Rats
  • Rats, Wistar
  • Recovery of Function
  • Sulfones / administration & dosage
  • Sulfones / pharmacology*
  • Time Factors
  • Troponin I / metabolism
  • Ultrasonography


  • Calcium Channel Blockers
  • Cardiotonic Agents
  • Indoles
  • Myosin Light Chains
  • Protein Kinase Inhibitors
  • Sulfones
  • Troponin I
  • myosin light chain 2
  • SR 33805
  • Cyclic AMP-Dependent Protein Kinases
  • Cardiac Myosins